ST. PAUL, MN -- November 28, 2006 -- Spinal cord injury patients
with moderate to severe nerve pain experienced less pain and in some
cases no pain while taking the drug pregabalin, according to a study
published in the November 28, 2006, issue of Neurology, the scientific
journal of the American Academy of Neurology.
"The findings are promising as spinal cord injury
pain is a condition which generally responds poorly to currently
available treatments," said study author Philip J. Siddall, MBBS, PhD,
with Royal North Shore Hospital in Sydney, Australia.
The study, considered to be the largest randomized
controlled trial of spinal cord injury patients with nerve pain,
involved 137 adults in Australia over a 12-week period. Half of the
group received pregabalin; the other half received a placebo.
Researchers found at the end of 12 weeks, fewer than 16 percent of
patients taking pregabalin had severe pain compared with 43 percent in
the placebo group. And over one-third of patients in the pregabalin
group had no or mild pain.
The study also found pregabalin reduced sleep and anxiety problems compared to the placebo group.
"Pregabalin was significantly more effective in relieving pain,
improving sleep, anxiety, and overall well-being in patients with
spinal cord injury compared to placebo," said Siddall. "Fifty-seven
percent of patients taking pregabalin said they felt better overall
compared to 21 percent in the placebo group."
Siddall said the pain relief was rapid as the pregabalin group had
significant pain relief after the first week of the study. The drug's
most common side effects were dizziness and drowsiness.
Nerve pain is estimated to occur in up to 40 percent of people with
spinal cord injury. According to the National Spinal Cord Injury
Association, as many as 450,000 people in the United States have spinal
cord injuries and about 11,000 people sustain new spinal cord injuries
each year.
Pregabalin is currently used to treat two of the most common types
of nerve pain: diabetic nerve pain and pain after shingles. The drug is
manufactured by Pfizer Inc., which supported this study.
The American Academy of Neurology, an association of more than
19,000 neurologists and neuroscience professionals, is dedicated to
improving patient care through education and research. A neurologist is
a doctor with specialized training in diagnosing, treating and managing
disorders of the brain and nervous system such as stroke, Alzheimer's
disease, epilepsy, Parkinson disease, and Multiple Sclerosis.
SOURCE: American Academy of Neurology